Equities

Shanghai Shyndec Pharmaceutical Co Ltd

600420:SHH

Shanghai Shyndec Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)10.05
  • Today's Change-0.11 / -1.08%
  • Shares traded9.65m
  • 1 Year change-1.08%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products are antibiotics, circulatory system drugs and biological products, including garlic oil soft capsules, lecithin soft capsules and deep-sea fish oil soft capsules. Its bulk pharmaceutical chemicals (BPCs) include macrolide antibiotics, antiviral, anti-tumor, cardiovascular, hormones and weight loss drugs. The Company also offers topical preparations, such as gynecological suppositories and dermatology preparations.

  • Revenue in CNY (TTM)11.59bn
  • Net income in CNY1.07bn
  • Incorporated1996
  • Employees11.61k
  • Location
    Shanghai Shyndec Pharmaceutical Co LtdNo. 378 Jianlu Road, Pudong New AreaSHANGHAI 200137ChinaCHN
  • Phone+86 2 152372865
  • Fax+86 2 158480136
  • Websitehttp://www.shyndec.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sunshine Guojian Pharmcutcl Shngh Co Ltd1.13bn329.37m11.78bn965.0035.772.36--10.400.5340.5341.848.090.21711.476.751,173,933.006.111.326.421.4175.8680.7428.126.556.30--0.018.2522.84-2.35497.63-4.4421.22--
Jiangsu Sinopep Allsin Bphrmctcl Co Ltd1.46bn348.25m11.82bn1.55k34.504.83--8.071.561.566.6811.140.44151.334.30947,744.5010.785.8615.227.5964.9555.4124.4117.201.0335.280.335227.5958.6932.2426.2029.9927.32--
Jiang Zhong Pharmaceutical Co Ltd4.27bn750.04m12.10bn4.01k16.053.11--2.841.201.206.816.180.69273.9314.221,062,816.0013.2710.8220.4015.0864.2865.0219.1518.171.16--0.010882.8813.0020.1218.408.5411.4740.99
Liaoning Cheng Da Co Ltd11.50bn195.93m12.59bn3.36k66.000.4262--1.100.12470.12477.4919.310.23995.116.343,425,308.00-0.0433.59-0.06135.2115.1214.15-0.17919.890.9012--0.310215.93-25.97-10.97-80.95-21.267.04--
Shanghai Shyndec Pharmaceutical Co Ltd11.59bn1.07bn13.63bn11.61k12.791.05--1.180.79450.79458.649.670.59533.176.50998,061.506.874.8510.068.1737.3243.0011.547.031.97--0.10417.52-6.861.2910.21-0.3897-2.210.00
Tonghua Dongbao Pharmaceutical Co Ltd2.45bn452.54m14.27bn3.20k34.272.20--5.830.21010.21011.253.280.35270.6974.25766,304.106.5118.686.8519.6878.8078.7318.4739.203.07--0.052441.7310.692.69-26.176.85-14.754.56
Zhejiang Medicine Co., Ltd.8.26bn472.71m14.42bn6.23k29.901.45--1.750.50170.50178.7210.340.64552.816.181,326,750.002.704.323.415.6832.2836.574.186.281.773.640.075558.72-3.962.59-20.373.3412.650.00
Suzhou Zelgen Biopharmaceuticals Co Ltd407.21m-230.89m15.59bn867.00--9.95--38.28-0.8669-0.86691.535.920.13640.24843.38469,674.00-8.44-27.13-13.16-39.2092.3192.75-61.85-220.712.19--0.3791--27.83211.8139.08--41.38--
Data as of Sep 20 2024. Currency figures normalised to Shanghai Shyndec Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

5.42%Per cent of shares held by top holders
HolderShares% Held
E Fund Management Co., Ltd.as of 30 Jun 202429.55m2.20%
China Merchants Fund Management Co., Ltd.as of 30 Sep 202313.59m1.01%
Monetary Authority of Macao (Investment Management)as of 30 Sep 20239.27m0.69%
CCB Principal Asset Management Co., Ltd.as of 31 Dec 20234.86m0.36%
GF Fund Management Co., Ltd.as of 31 Dec 20234.63m0.35%
The Vanguard Group, Inc.as of 04 Sep 20243.40m0.25%
China Asset Management Co., Ltd.as of 31 Dec 20232.02m0.15%
Dimensional Fund Advisors LPas of 05 Sep 20242.00m0.15%
Tian Hong Asset Management Co., Ltd.as of 31 Dec 20231.92m0.14%
HSBC Jintrust Fund Management Co. Ltd.as of 31 Dec 20231.43m0.11%
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.